Lee Schwartzberg
机构: Professor of Medicine, University of Tennessee Health Science Center
每年引用次数
引用次数
引用: 23,656
H-指数: 73
I10-指数 : 284
出版物: 971
Management of Chemotherapy-induced Neutropoenia
LeeS Schwartzberg ,
European Oncology and Haematology 04 ( 01) 26
2008
Autologous bone marrow transplantation in primary breast cancer : the American experience
D. Douer , C. F. Lemaistre , M. W. Schuster , W. P. Peters
Bone Marrow Transplantation 15 ( 1)
6
1995
Evidence-based treatment protocol (ETP) usage in community oncology clinics
P. W. Cobb , R. Hermann , H. Lebos , H. Tamim
Journal of Clinical Oncology 26 6621 -6621
2008
A phase II study of concurrent chemoradiotherapy with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer
R. S. Hughes , A. B. Sandler , A. K. Jain , A. Dowlati
Journal of Clinical Oncology 26 7565 -7565
2008
Phase I dosage-finding and pharmacokinetic (PK) study of intravenous topotecan and oral erlotinib in patients (pts) with refractory solid tumors
L. S. Schwartzberg , C. F. Stewart , P. Schaiquevich , P. Legenne
Journal of Clinical Oncology 26 2549 -2549
1
2008
Preliminary results of a phase 2 study of ABT-751 in patients (pts) with taxane-refractory non-small cell lung carcinoma (NSCLC)
A. M. Mauer , L. Szeto , R. J. Belt , L. S. Schwartzberg
Journal of Clinical Oncology 23 7137 -7137
6
2005
Final results of the National Patient Impact Initiative
K. W. Tauer , B. V. Fortner , L. Zhu , L. Ma
Journal of Clinical Oncology 23 8128 -8128
2005
A prospective investigation of chemotherapy induced neutropenia (CIN) and quality of life (QoL)
B. V. Fortner , A. C. Houts , G. Johnson , L. S. Schwartzberg
Journal of Clinical Oncology 23 8178 -8178
2
2005
Randomized phase II trial of two different schedules of carboplatin (C) and paclitaxel (P) + trastuzumab (T) as first line treatment for metastatic breast cancer (MBC)
K. Tauer , L. S. Schwartzberg , A. Epperson , B. V. Fortner
Journal of Clinical Oncology 24 10697 -10697
2006
Patterns of adjuvant hormonal therapy (AHT) usage in early stage breast cancer (ESBC)
P. Cobb , L. S. Schwartzberg , K. Kulig , A. Johns
Journal of Clinical Oncology 24 10695 -10695
2006
Phase II trial of nanoparticle albumin-bound paclitaxel (ABX) + capecitabine (XEL) in first line treatment of metastatic breast cancer (MBC)
D. Mintzer , L. S. Schwartzberg , P. Cobb , D. Henry
Journal of Clinical Oncology 24 10731 -10731
2006
Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and gemcitabine/cisplatin (GC) for the treatment of advanced solid malignancies
J. Crawford , H. A. Burris III , M. Stein , J. Stephenson
Journal of Clinical Oncology 24 13005 -13005
11
2006
Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC)
A. D. Seidman , A. Brufsky , R. H. Ansari , J. R. Rubinsak
Journal of Clinical Oncology 27 1000 -1000
5
2009
Phase IIb double-blind, randomized, placebo-controlled trials for the efficacy and safety of sorafenib in patients (pts) with metastatic or locally advanced breast cancer (BC): Review of the Trials to Investigate the Effects of Sorafenib in BC (TIES) program
J. Baselga , L. Gianni , W. J. Gradishar , C. Hudis
Journal of Clinical Oncology 27
4
2009
An open-label, dose-escalating study of Maxy-G34, a novel potent, long-acting Pegylated G-CSF, compared with pegfilgrastim (PF) for the treatment of chemotherapy induced neutropenia (CIN)
L. S. Schwartzberg , S. L. Sankar , D. Apt , E. Goldstein
Journal of Clinical Oncology 27
4
2009
Peripheral Blood Stem Cell Mobilization in the Outpatient Setting
L. S. Schwartzberg
Peripheral Blood Stem Cell Autografts 177 -184
5
1993
The importance of histology when evaluating the cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced non-small cell lung cancer
C. E. Muehlenbein , R. W. Klein , A. M. Liepa , S. M. Babineaux
Journal of Clinical Oncology 27
2009
An observational study of the impact of ethnicity on patients treated for non-small cell lung cancer (NSCLC) in the second-line setting with pemetrexed: Preliminary results in African Americans
A. C. Girvan , G. Peltz , E. Pennella , G. Pohl
Journal of Clinical Oncology 27 ( 15_suppl) e20624 -e20624
2009
A regional subgroup analysis of a multinational, double-blind, randomized, placebo-controlled, phase IIb study evaluating sorafenib (SOR) with paclitaxel (PAC) in patients (pts) with advanced breast cancer (BC).
T. P. Sahoo , V. G. Kaklamani , D. Lokanatha , V. Raina
Journal of Clinical Oncology 28 1114 -1114
1
2010
Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC).
N. C. Tebbutt , D. Kotasek , H. A. Burris , L. S. Schwartzberg
Journal of Clinical Oncology 28 3538 -3538
9
2010